Siemens to Close Fast Track Diagnostics Business
By LabMedica International staff writers Posted on 19 Mar 2024 |
Siemens Healthineers (Erlangen, Germany) has announced its intention to close its Fast Track Diagnostics unit, a small collection of polymerase chain reaction (PCR) testing products that is part of the Diagnostics business. This product portfolio is sold mainly in the European market. The demand for the Fast Track Diagnostics portfolio has declined significantly since the peak of the COVID-19 pandemic.
Siemens offers in vitro diagnostic test solutions for almost every clinical environment. Its central laboratory analyzers are utilized in research laboratories, clinical laboratories of local community hospitals, independent specialty laboratories, and in the world’s largest reference labs. The company’s point-of-care testing solutions support care everywhere from remote pop-up health clinics to community physician offices, and outpatient care facilities to patients’ bedsides in hospital units.
Siemens has differentiated its in vitro diagnostic test offerings with flexible, scalable, and integrated automation capabilities that improve control over laboratory testing and operational workflows. Fast Track Diagnostics is a minor player in the molecular diagnostics space and represents a very small part of the overall revenue of Siemens’ Diagnostics business. Siemens intends to close the Fast Track Diagnostics unit by September 2024.
Related Links:
Siemens Healthineers
Latest Industry News
- Beckman Coulter and Scopio Labs Add World's First Digital Bone Marrow Imaging and Analysis to Long-Term Partnership
- Roche Expands Digital Pathology Open Environment with Integration of Advanced AI Algorithms from New Collaborators
- Qiagen and Eli Lilly to Develop First QIAstat-Dx IVD Panel for Neurodegenerative Applications
- QIAGEN and AstraZeneca Expand Collaboration into New Disease Areas
- MEDICA 2024 + COMPAMED 2024: Adapted Hall Layout for Better Integration
- Global Coagulation Testing Driven by Increasing Blood Disorders and Surgical Interventions
- Sysmex and QIAGEN Expand Collaboration in Genetic Testing
- MEDICA 2024 + COMPAMED 2024 International and Diverse Trade Fairs to Welcome Over 6,000 Exhibitors
- Beckman Coulter Licenses Alzpath's Proprietary P-tau 217 Antibody to Develop Alzheimer's Blood Test
- Global Urinalysis Market Driven by Technological Advancements in POC Testing
- Roche and Hitachi High-Tech Extend 46-Year Partnership for Breakthroughs in Diagnostic Testing
- Danaher and Johns Hopkins University Collaborate to Improve Neurological Diagnosis
- Beckman Coulter and MeMed Expand Host Immune Response Diagnostics Partnership
- Thermo Fisher and Bio-Techne Enter Into Strategic Distribution Agreement for Europe
- ECCMID Congress Name Changes to ESCMID Global
- Bosch and Randox Partner to Make Strategic Investment in Vivalytic Analysis Platform